The Breast CARE Study: Capecitabine (Xeloda) combined with Rhenium-188-HEDP in breast cancer patients with bone metastases; a Re-188-HEDP phase I dose escalation study and phase II efficacy study.

Trial Profile

The Breast CARE Study: Capecitabine (Xeloda) combined with Rhenium-188-HEDP in breast cancer patients with bone metastases; a Re-188-HEDP phase I dose escalation study and phase II efficacy study.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2012

At a glance

  • Drugs Capecitabine (Primary) ; Rhenium-188-etidronic acid (Primary)
  • Indications Bone metastases; Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Breast CARE Study
  • Most Recent Events

    • 22 Feb 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 07 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top